Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Study Objective. To compare the lipid-lowering effects of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease. Design. Open label, fixed-dosage, retrospective-prospective, one-way crossover from gemfibrozil to fenofibrate. Setting. University-affiliated outpatient clinics. Patients. Eighty patients with coronary heart disease with a baseline lowdensity lipoprotein cholesterol (LDL) level above 130 mg/dl or a triglyceride level of 200 mg/dl or higher who had been receiving gemfibrozil 600 mg twice/day Thirty-nine (49%) patients had received concomitant therapy with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) for a minimum of 9 months. Intervention. All patients received gemfibrozil 600 mg twice/day for at least 3 months before being switched to fenofibrate 201 mg/day. Patients receiving concomitant statin therapy before crossover continued the statin at the same dosage after crossover. Before crossover, a fasting lipid profile was determined and patients were queried about the side effects of lipidlowering therapy. A repeat fasting lipid profile was obtained 12 weeks after the crossover. Measurements and Main Results. Patients were stratified into those receiving versus those not receiving concomitant statin therapy. In both of these groups, fenofibrate was associated with significantly greater reductions in total cholesterol, LDL, and triglycerides than gemfibrozil (all p

Original languageEnglish
Pages (from-to)1527-1532
Number of pages6
JournalPharmacotherapy
Volume22
Issue number12 I
StatePublished - Dec 1 2002

Fingerprint

Gemfibrozil
Fenofibrate
Coronary Disease
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipids
Fasting
Therapeutics
Ambulatory Care Facilities
Oxidoreductases
Triglycerides
Cholesterol

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease. / Packard, Kathleen A.; Backes, James M.; Lenz, Thomas L.; Wurdeman, Richard L.; Destache, Christopher J.; Hilleman, Daniel E.

In: Pharmacotherapy, Vol. 22, No. 12 I, 01.12.2002, p. 1527-1532.

Research output: Contribution to journalArticle

@article{ca81e23e2a3e46b8b0eb6a7b79967263,
title = "Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease",
abstract = "Study Objective. To compare the lipid-lowering effects of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease. Design. Open label, fixed-dosage, retrospective-prospective, one-way crossover from gemfibrozil to fenofibrate. Setting. University-affiliated outpatient clinics. Patients. Eighty patients with coronary heart disease with a baseline lowdensity lipoprotein cholesterol (LDL) level above 130 mg/dl or a triglyceride level of 200 mg/dl or higher who had been receiving gemfibrozil 600 mg twice/day Thirty-nine (49{\%}) patients had received concomitant therapy with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) for a minimum of 9 months. Intervention. All patients received gemfibrozil 600 mg twice/day for at least 3 months before being switched to fenofibrate 201 mg/day. Patients receiving concomitant statin therapy before crossover continued the statin at the same dosage after crossover. Before crossover, a fasting lipid profile was determined and patients were queried about the side effects of lipidlowering therapy. A repeat fasting lipid profile was obtained 12 weeks after the crossover. Measurements and Main Results. Patients were stratified into those receiving versus those not receiving concomitant statin therapy. In both of these groups, fenofibrate was associated with significantly greater reductions in total cholesterol, LDL, and triglycerides than gemfibrozil (all p",
author = "Packard, {Kathleen A.} and Backes, {James M.} and Lenz, {Thomas L.} and Wurdeman, {Richard L.} and Destache, {Christopher J.} and Hilleman, {Daniel E.}",
year = "2002",
month = "12",
day = "1",
language = "English",
volume = "22",
pages = "1527--1532",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "12 I",

}

TY - JOUR

T1 - Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease

AU - Packard, Kathleen A.

AU - Backes, James M.

AU - Lenz, Thomas L.

AU - Wurdeman, Richard L.

AU - Destache, Christopher J.

AU - Hilleman, Daniel E.

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Study Objective. To compare the lipid-lowering effects of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease. Design. Open label, fixed-dosage, retrospective-prospective, one-way crossover from gemfibrozil to fenofibrate. Setting. University-affiliated outpatient clinics. Patients. Eighty patients with coronary heart disease with a baseline lowdensity lipoprotein cholesterol (LDL) level above 130 mg/dl or a triglyceride level of 200 mg/dl or higher who had been receiving gemfibrozil 600 mg twice/day Thirty-nine (49%) patients had received concomitant therapy with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) for a minimum of 9 months. Intervention. All patients received gemfibrozil 600 mg twice/day for at least 3 months before being switched to fenofibrate 201 mg/day. Patients receiving concomitant statin therapy before crossover continued the statin at the same dosage after crossover. Before crossover, a fasting lipid profile was determined and patients were queried about the side effects of lipidlowering therapy. A repeat fasting lipid profile was obtained 12 weeks after the crossover. Measurements and Main Results. Patients were stratified into those receiving versus those not receiving concomitant statin therapy. In both of these groups, fenofibrate was associated with significantly greater reductions in total cholesterol, LDL, and triglycerides than gemfibrozil (all p

AB - Study Objective. To compare the lipid-lowering effects of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease. Design. Open label, fixed-dosage, retrospective-prospective, one-way crossover from gemfibrozil to fenofibrate. Setting. University-affiliated outpatient clinics. Patients. Eighty patients with coronary heart disease with a baseline lowdensity lipoprotein cholesterol (LDL) level above 130 mg/dl or a triglyceride level of 200 mg/dl or higher who had been receiving gemfibrozil 600 mg twice/day Thirty-nine (49%) patients had received concomitant therapy with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) for a minimum of 9 months. Intervention. All patients received gemfibrozil 600 mg twice/day for at least 3 months before being switched to fenofibrate 201 mg/day. Patients receiving concomitant statin therapy before crossover continued the statin at the same dosage after crossover. Before crossover, a fasting lipid profile was determined and patients were queried about the side effects of lipidlowering therapy. A repeat fasting lipid profile was obtained 12 weeks after the crossover. Measurements and Main Results. Patients were stratified into those receiving versus those not receiving concomitant statin therapy. In both of these groups, fenofibrate was associated with significantly greater reductions in total cholesterol, LDL, and triglycerides than gemfibrozil (all p

UR - http://www.scopus.com/inward/record.url?scp=0036894204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036894204&partnerID=8YFLogxK

M3 - Article

C2 - 12495163

AN - SCOPUS:0036894204

VL - 22

SP - 1527

EP - 1532

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 12 I

ER -